Related Experiment Video
Updated: May 24, 2026
09:39
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
Published on: February 7, 2021
Hydrocolloid-based nutraceutical delivery systems.
Srinivas Janaswamy1, Susanne R Youngren
1Whistler Center for Carbohydrate Research, Department of Food Science, Purdue University, 745 Agriculture Mall Drive, West Lafayette, IN 47907-2009, USA. janaswam@purdue.edu
Food & Function
|March 16, 2012
Summary
Hydrocolloid matrices offer a novel solution for delivering nutraceuticals, like curcumin, in their active form. This approach enhances stability and enables sustained release, paving the way for improved functional foods.
Area of Science:
- Food Science
- Materials Science
- Biotechnology
Background:
- Nutraceuticals possess significant health benefits but face challenges in water solubility and stability.
- Current limitations hinder the effective utilization and consumption of many beneficial nutraceutical compounds.
- Developing stable delivery systems is crucial for unlocking the full potential of nutraceuticals.
Purpose of the Study:
- To develop an effective and stable delivery system for nutraceuticals.
- To utilize inexpensive, non-toxic, and GRAS-status hydrocolloid matrices for nutraceutical encapsulation.
- To demonstrate the capability of hydrocolloid matrices in protecting and controlling the release of active nutraceuticals.
Main Methods:
- Model nutraceutical curcumin was encapsulated within an iota-carrageenan hydrocolloid matrix.
- The structural integrity and stability of the encapsulated curcumin within the matrix were assessed.
- The release profile of curcumin from the iota-carrageenan matrix was investigated.
Main Results:
- The iota-carrageenan network successfully encapsulated curcumin molecules, maintaining their active form.
- The hydrocolloid matrix provided protection against melting and degradation of curcumin.
- Sustained release of curcumin from the iota-carrageenan matrix was achieved.
Conclusions:
- Hydrocolloid matrices, specifically iota-carrageenan, offer a promising strategy for the stable delivery of nutraceuticals.
- This method overcomes the limitations of poor solubility and instability associated with many nutraceuticals.
- The findings support the development of advanced functional and medicinal foods with enhanced nutraceutical efficacy.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:11Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
01:28Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...